208
Views
6
CrossRef citations to date
0
Altmetric
Case Reports

Successful treatment of rectal ulcers in a patient with systemic lupus erythematosus using corticosteroids and tacrolimus

, , , , , , , , , & show all
Pages 357-360 | Received 20 Jun 2012, Accepted 19 Sep 2012, Published online: 05 Mar 2014

References

  • Lee CK, Ahn MS, Lee EY, Shin JH, Cho YS, Ha HK, et al. Acute abdominal pain in systemic lupus erythematosus: focus on lupus enteritis (gastrointestinal vasculitis). Ann Rheum Dis. 2002;61: 547–550.
  • Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology. 1999;38: 917–932.
  • Grimbacher B, Huber M, Kempis J, Kalden P, Uhl M, Kohler G, et al. Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature. Br J Rheumatol. 1998;37: 1023–1028.
  • Teramoto J, Takahashi Y, Katsuki S, Sato T, Sakamaki S, Kobayashi D, et al. Systemic lupus erythematosus with a giant rectal ulcer and perforation. Intern Med. 1999;38: 643–649.
  • Miyahara S, Ito S, Soeda A, Chino Y, Hayashi T, Takahashi R, et al. Two cases of systemic lupus erythematosus complicated with colonic ulcers. Intern Med. 2005;44: 1298–1306.
  • Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130: 1655–1663.
  • Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63: 1247–1297.
  • Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Gritsch HA, Corry RJ, et al. The superiority of tacrolimus in renal transplant recipients—the Pittsburgh experience. Clin Transplant. 1995:199–205.
  • Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn’s disease: a single-center experience. Inflamm Bowel Dis. 2008;14: 7–12.
  • Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 2005;68: 813–817.
  • Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19: 606–615.
  • Morimoto S, Watanabe T, Lee S, Amano H, Kanamaru Y, Ohsawa I, et al. Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus. Mod Rheumatol. 2010;20: 291–294.
  • Takahashi S, Hiromura K, Sakurai N, Matsumoto T, Ikeuchi H, Maeshima A, et al. Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol. 2011;21: 282–289.
  • Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007;19: 238–245.
  • Kusunoki Y, Tanaka N, Kaneko K, Yamamoto T, Endo H, Kawai S. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. Mod Rheumatol. 2009;19: 616–621.
  • Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Nishi E, et al. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol Int. 2011;31: 757–763.
  • Maruoka H, Honda S, Takeo M, Koga T, Fukuda T, Aizawa H. Tacrolimus treatment for refractory lupus cystitis. Mod Rheumatol. 2006;16: 264–266.
  • Watanabe H, Hirase N, Goda H, Nishikawa H, Ikuyama S. Oral low-dose tacrolimus therapy for refractory hemophagocytic syndrome associated with systemic lupus erythematosus. Mod Rheumatol. 2012;22: 284–289.
  • Nitzan O, Elias M, Saliba WR. Systemic lupus erythematosus and inflammatory bowel disease. Eur J Intern Med. 2006;17: 313–318.
  • Yuasa S, Suwa A, Hirakata M, Hibi N, Iwao Y, Koizumi K, et al. A case of systemic lupus erythematosus presenting with rectal ulcers as the initial clinical manifestation of disease. Clin Exp Rheumatol. 2002;20: 407–410.
  • Buck AC, Serebro LH, Quinet RJ. Subacute abdominal pain requiring hospitalization in a systemic lupus erythematosus patient: a retrospective analysis and review of the literature. Lupus. 2001;10: 491–495.
  • Medina F, Ayala A, Jara LJ, Becerra M, Miranda JM, Fraga A. Acute abdomen in systemic lupus erythematosus: the importance of early laparotomy. Am J Med. 1997;103: 100–105.
  • Byun JY, Ha HK, Yu SY, Min JK, Park SH, Kim HY, et al. CT features of systemic lupus erythematosus in patients with acute abdominal pain: emphasis on ischemic bowel disease. Radiology. 1999;211: 203–209.
  • Luman W, Chua KB, Cheong WK, Ng HS. Gastrointestinal manifestations of systemic lupus erythematosus. Singapore Med J. 2001;42: 380–384.
  • Takeuchi T, Tsuzaka K, Abe T, Yoshimoto K, Shiraishi K, Kameda H, et al. T cell abnormalities in systemic lupus erythematosus. Autoimmunity. 2005;38: 339–346.
  • Fellermann K, Herrlinger KR, Witthoeft T, Homann N, Ludwig D, Stange EF. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. Transpl Proc. 2001;33: 2247–2248.
  • Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009;15: 935–950.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.